ABSTRACT
The Southern Ocean greatly contributes to the regulation of the global climate by controlling important heat and carbon exchanges between the atmosphere and the ocean. Rates of climate change on decadal timescales are therefore impacted by oceanic processes taking place in the Southern Ocean, yet too little is known about these processes. Limitations come both from the lack of observations in this extreme environment and its inherent sensitivity to intermittent processes at scales that are not well captured in current Earth system models. The Southern Ocean Carbon and Heat Impact on Climate programme was launched to address this knowledge gap, with the overall objective to understand and quantify variability of heat and carbon budgets in the Southern Ocean through an investigation of the key physical processes controlling exchanges between the atmosphere, ocean and sea ice using a combination of observational and modelling approaches. Here, we provide a brief overview of the programme, as well as a summary of some of the scientific progress achieved during its first half. Advances range from new evidence of the importance of specific processes in Southern Ocean ventilation rate (e.g. storm-induced turbulence, sea-ice meltwater fronts, wind-induced gyre circulation, dense shelf water formation and abyssal mixing) to refined descriptions of the physical changes currently ongoing in the Southern Ocean and of their link with global climate. This article is part of a discussion meeting issue 'Heat and carbon uptake in the Southern Ocean: the state of the art and future priorities'.
ABSTRACT
BACKGROUND: Outcomes for patients with high-risk diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy are suboptimal but, to date, no alternative regimen has been shown to improve survival rates. This phase 2 trial aimed to assess the efficacy of a Burkitt-like approach for high-risk DLBCL using the dose-intense R-CODOX-M/R-IVAC regimen. PATIENTS AND METHODS: Eligible patients were aged 18-65 years with stage II-IV untreated DLBCL and an International Prognostic Index (IPI) score of 3-5. Patients received alternating cycles of CODOX-M (cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate) alternating with IVAC chemotherapy (ifosfamide, etoposide and high-dose cytarabine) plus eight doses of rituximab. Response was assessed by computed tomography after completing all four cycles of chemotherapy. The primary end point was 2-year progression-free survival (PFS). RESULTS: A total of 111 eligible patients were registered; median age was 50 years, IPI score was 3 (60.4%) or 4/5 (39.6%), 54% had a performance status ≥2 and 9% had central nervous system involvement. A total of 85 patients (76.6%) completed all four cycles of chemotherapy. There were five treatment-related deaths (4.3%), all in patients with performance status of 3 and aged >50 years. Two-year PFS for the whole cohort was 67.9% [90% confidence interval (CI) 59.9-74.6] and 2-year overall survival was 76.0% (90% CI 68.5-82.0). The ability to tolerate and complete treatment was lower in patients with performance status ≥2 who were aged >50 years, where 2-year PFS was 43.5% (90% CI 27.9-58.0). CONCLUSIONS: This trial demonstrates that R-CODOX-M/R-IVAC is a feasible and effective regimen for the treatment of younger and/or fit patients with high-risk DLBCL. These encouraging survival rates demonstrate that this regimen warrants further investigation against standard of care. TRIAL REGISTRATION: ClinicalTrials.gov (NCT00974792) and EudraCT (2005-003479-19).
Subject(s)
Burkitt Lymphoma , Lymphoma, Large B-Cell, Diffuse , Adolescent , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Burkitt Lymphoma/drug therapy , Cyclophosphamide/therapeutic use , Disease-Free Survival , Doxorubicin/therapeutic use , Humans , Ifosfamide/therapeutic use , Lymphoma, Large B-Cell, Diffuse/drug therapy , Middle Aged , Prednisone/therapeutic use , Rituximab/therapeutic use , United Kingdom , Vincristine/therapeutic use , Young AdultABSTRACT
OBJECTIVES: Home is considered the preferred place of death for many, but patients with haematological malignancies (leukaemias, lymphomas and myeloma) die in hospital more often than those with other cancers and the reasons for this are not wholly understood. We examined preferred and actual place of death among people with these diseases. METHODS: The study is embedded within an established population-based cohort of patients with haematological malignancies. All patients diagnosed at two of the largest hospitals in the study area between May 2005 and April 2008 with acute myeloid leukaemia, diffuse large B-cell lymphoma or myeloma, who died before May 2010 were included. Data were obtained from medical records and routine linkage to national death records. RESULTS: 323 deceased patients were included. A total of 142 (44%) had discussed their preferred place of death; 45.8% wanted to die at home, 28.2% in hospital, 16.9% in a hospice, 5.6% in a nursing home and 3.5% were undecided; 63.4% of these died in their preferred place. Compared to patients with evidence of a discussion, those without were twice as likely to have died within a month of diagnosis (14.8% vs 29.8%). Overall, 240 patients died in hospital; those without a discussion were significantly more likely to die in hospital than those who had (p≤0.0001). Of those dying in hospital, 90% and 75.8% received haematology clinical input in the 30 and 7â days before death, respectively, and 40.8% died in haematology areas. CONCLUSIONS: Many patients discussed their preferred place of death, but a substantial proportion did not and hospital deaths were common in this latter group. There is scope to improve practice, particularly among those dying soon after diagnosis. We found evidence that some people opted to die in hospital; the extent to which this compares with other cancers is of interest.
Subject(s)
Attitude to Death , Hematologic Neoplasms/epidemiology , Patient Preference , Cohort Studies , England/epidemiology , Female , Hematologic Neoplasms/psychology , Humans , Leukemia, Myeloid, Acute/epidemiology , Leukemia, Myeloid, Acute/psychology , Lymphoma, Large B-Cell, Diffuse/epidemiology , Lymphoma, Large B-Cell, Diffuse/psychology , Male , Multiple Myeloma/epidemiology , Multiple Myeloma/psychology , Palliative Care , State MedicineABSTRACT
BACKGROUND: Population-based information about cancer occurrence and survival are required to inform clinical practice and research; but for most lymphomas data are lacking. METHODS: Set within a socio-demographically representative UK population of nearly 4 million, lymphoma data (N=5796) are from an established patient cohort. RESULTS: Incidence, survival (overall and relative) and prevalence estimates for >20 subtypes are presented. With few exceptions, males tended to be diagnosed at younger ages and have significantly (P<0.05) higher incidence rates. Differences were greatest at younger ages: the <15 year male/female rate ratio for all subtypes combined being 2.2 (95% CI 1.3-3.4). These gender differences impacted on prevalence; most subtype estimates being significantly (P<0.05) higher in males than females. Outcome varied widely by subtype; survival of patients with nodular lymphocyte predominant Hodgkin lymphoma approached that of the general population, whereas less than a third of those with other B-cell (e.g., mantle cell) or T-cell (e.g., peripheral-T) lymphomas survived for ≥5 years. No males/female survival differences were detected. CONCLUSIONS: Major strengths of our study include completeness of ascertainment, world-class diagnostics and generalisability. The marked variations demonstrated confirm the requirement for 'real-world' data to inform aetiological hypotheses, health-care planning and the future monitoring of therapeutic changes.
Subject(s)
Hematologic Neoplasms/epidemiology , Hematologic Neoplasms/mortality , Lymphoma/epidemiology , Lymphoma/mortality , Adolescent , Adult , Aged , Child , Child, Preschool , Cohort Studies , Female , Follow-Up Studies , Humans , Incidence , Infant , Infant, Newborn , Lymphoma/classification , Male , Middle Aged , Prevalence , Prognosis , Survival Rate , United Kingdom/epidemiology , Young AdultABSTRACT
OBJECTIVE: To develop and implement a methodology for capturing complete haematological malignancy pathway data and use it to identify variations in specialist palliative care (SPC) referrals. METHODS: In our established UK population-based patient cohort, 323 patients were diagnosed with acute myeloid leukaemia, diffuse large B-cell lymphoma or myeloma between May 2005 and April 2008, and died before April 2010. A day-by-day calendar approach was devised to collect pathway data, including SPC referrals, to supplement routinely collected information on clinical presentation, diagnosis, treatment, response, and date and place of death. RESULTS: 155 (47.9%) of the 323 patients had at least one SPC referral. The likelihood of referral increased with survival (OR 6.58, 95% CIs 3.32 to 13.03 for patients surviving ≥1â year compared to ≤1â month from diagnosis), and varied with diagnosis (OR 1.96, CIs 1.15 to 3.35 for myeloma compared to acute myeloid leukaemia). Compared to patients dying in hospital, those who died at home or in a hospice were also more likely to have had an SPC referral (OR 3.07, CIs 1.59 to 5.93 and 4.74, CIs 1.51 to 14.81, respectively). No associations were found for age and sex. CONCLUSIONS: Our novel approach efficiently captured pathway data and SPC referrals, revealing evidence of greater integration between haematology and SPC services than previously reported. The likelihood of referral was much higher among those dying outside hospital, and variations in practice were observed by diagnosis, emphasising the importance of examining diseases individually.
Subject(s)
Leukemia, Myeloid, Acute/therapy , Lymphoma, Large B-Cell, Diffuse/therapy , Multiple Myeloma/therapy , Palliative Care/statistics & numerical data , Referral and Consultation/statistics & numerical data , Aged , Critical Pathways/statistics & numerical data , Female , Humans , Leukemia, Myeloid, Acute/mortality , Lymphoma, Large B-Cell, Diffuse/mortality , Male , Middle Aged , Multiple Myeloma/mortality , Palliative Care/methods , Retrospective Studies , Specialization , Survival AnalysisABSTRACT
OBJECTIVES: To examine contemporary survival patterns in the general population of patients diagnosed with chronic myeloid leukaemia (CML), and to identify patient groups with less than optimal outcomes. DESIGN: Prospective population-based cohort. SETTING: The UK's Haematological Malignancy Research Network (catchment population 3.6 million, with >2000 new haematological malignancies diagnosed annually). PARTICIPANTS: All patients newly diagnosed with CML, from September 2004 to August 2011 and followed up to 31 March 2013. MAIN OUTCOME MEASURE: Incidence and survival. RESULTS: With a median diagnostic age of 59 years, the CML age standardised (European) incidence was 0.9/100 000 (95% CIs 0.8 to 0.9), 5-year overall survival was 78.9% (72.3 to 84.0) and 5-year relative survival 88.6% (81.0 to 93.3). The efficacy of treatment across all ages was clearly demonstrated; the relative survival curves for those under 60 and over 60 years being closely aligned. Survival findings were similar for men and women, but varied with deprivation; the age and sex adjusted HR being 3.43 (1.89 to 6.22) for deprivation categories 4-5 (less affluent) versus 1-3 (more affluent). None of these differences were attributable to the biological features of the disease. CONCLUSIONS: When therapy is freely provided, population-based survival for CML is similar to that reported in clinical trials, and age loses its prognostic significance. However, although most of the patients with CML now experience close to normal lifespans, those living in more deprived areas tend to have poorer outcomes, despite receiving the same clinical care. A significant improvement in overall population outcomes could be achieved if these socioeconomic differences, which may reflect the treatment compliance, could be eliminated.
Subject(s)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive , Protein Kinase Inhibitors , Age Factors , Antineoplastic Agents/economics , Antineoplastic Agents/therapeutic use , Female , Humans , Incidence , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality , Male , Middle Aged , Prognosis , Protein Kinase Inhibitors/economics , Protein Kinase Inhibitors/therapeutic use , Socioeconomic Factors , Survival Analysis , United Kingdom/epidemiologyABSTRACT
BACKGROUND: Ascertainment of cases and disease classification is an acknowledged problem for epidemiological research into haematological malignancies. METHODS: The Haematological Malignancy Research Network comprises an ongoing population-based patient cohort. All diagnoses (paediatric and adult) across two UK Cancer Networks (population 3.6 million, >2000 diagnoses annually, socio-demographically representative of the UK) are made by an integrated haematopathology laboratory. Diagnostics, prognostics, and treatment are recorded to clinical trial standards, and socio-demographic measures are routinely obtained. RESULTS: A total of 10,729 haematological malignancies (myeloid=2706, lymphoid=8023) were diagnosed over the 5 years, that is, from 2004 to 2009. Descriptive data (age, sex, and deprivation), sex-specific age-standardised (European population) rates, and estimated UK frequencies are presented for 24 sub-types. The age of patients ranged from 4 weeks to 99 years (median 70.6 years), and the male rate was more than double the female rate for several myeloid and lymphoid sub-types, this difference being evident in both children and adults. No relationship with deprivation was detected. CONCLUSION: Accurate population-based data on haematological malignancies can be collected to the standard required to deliver reproducible results that can be extrapolated to national populations. Our analyses emphasise the importance of gender and age as disease determinants, and suggest that aetiological investigations that focus on socio-economic factors are unlikely to be rewarding.
Subject(s)
Hematologic Neoplasms/classification , Hematologic Neoplasms/epidemiology , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Child , Child, Preschool , Cohort Studies , Epidemiologic Studies , Female , Health Services Research/methods , Hematologic Neoplasms/pathology , Humans , Infant , Male , Middle Aged , Risk Factors , Sex Factors , United Kingdom/epidemiology , Young AdultSubject(s)
Brachial Plexus Neuropathies/etiology , Melphalan/administration & dosage , Melphalan/therapeutic use , Multiple Myeloma/therapy , Peripheral Blood Stem Cell Transplantation , Humans , Male , Middle Aged , Peripheral Blood Stem Cell Transplantation/adverse effects , Transplantation, Autologous , Treatment OutcomeABSTRACT
Bone marrow aspiration and biopsy is a procedure of central importance in the diagnosis of haematological disease and is one that can be safely performed in the outpatient clinic using only local anaesthesia. We evaluated the role of inhaled nitrous oxide (Entonox) as an adjuvant to local anaesthesia (LA) in patients requiring bone examination. We prospectively studied the role of Entonox in patients attending our outpatient department who required bone marrow examination. All patients received LA with injected 2% lignocaine but patients were then assigned to either LA alone or LA plus inhaled Entonox. Following the procedure patients were given a questionnaire and asked to score the discomfort associated with the procedure. Twenty-eight of 85 patients (33%) who received LA alone scored their pain as 3 (severe) compared with seven of 51 patients (14%) who received LA plus Entonox, P = 0.013. No adverse events were associated with Entonox use. Forty-three of the 51 patients who received Entonox stated that they would prefer to use this method of anaesthesia again. We conclude that inhaled Entonox is a useful adjuvant to local anaesthesia for patients undergoing bone marrow examination.
Subject(s)
Anesthetics, Combined/administration & dosage , Anesthetics, Local/administration & dosage , Bone Marrow Examination/adverse effects , Lidocaine/administration & dosage , Nitrous Oxide/administration & dosage , Oxygen/administration & dosage , Pain/prevention & control , Administration, Inhalation , Drug Therapy, Combination , Humans , Pain/etiology , Pain Measurement/methods , Prospective Studies , Treatment OutcomeABSTRACT
In a laboratory study, groups of third-instar Blatta orientalis nymphs were reared to adulthood in arenas containing fenoxycarb (48 mg a.i./m2) treated ceramic or plywood tiles. The reproductive capacity of the emergent adults was assessed by pairing each individual with two untreated individuals of the opposite sex. Oothecal production, oothecal hatch and the numbers of nymphs emergent from each hatched ootheca were monitored. Exposure to 1-day-old deposits of fenoxycarb reduced adult emergence by 45-75% in comparison with an untreated control treatment. Substantial (> 40%) mortality also resulted when nymphs were exposed to deposits up to 3 months old on plywood and up to 6 months old on ceramic. Exposure to fenoxycarb significantly extended the time taken to reach adulthood of males contacting 6-month-old deposits on both surfaces, and of females contacting 1-year-old deposits on ceramic. Adult females exposed as nymphs to fenoxycarb were unable to produce oothecae, except one female laid a non-viable ootheca. Untreated females paired with treated males produced large numbers of oothecae of normal appearance but very low viability, with only 0-7.1% hatching. With marked effects on both development and reproduction in B.orientalis, fenoxycarb is a promising agent for control of this species.
Subject(s)
Carbamates/pharmacology , Cockroaches/drug effects , Metamorphosis, Biological/drug effects , Phenylcarbamates , Animals , Cockroaches/growth & development , Female , Male , Nymph/drug effects , Nymph/growth & development , Ovum , Reproduction/drug effectsABSTRACT
Progressive multifocal leucoencephalopathy (PML) is a rare disorder characterized by progressive demyelination within the brain. It is usually fatal and occurs when there are defects in cell-mediated immunity. We report a case of PML which developed following allogeneic bone marrow transplantation. It was preceded by the development of a persistent polyclonal expansion of large granular lymphocytes (LGLs) which appeared to rise as a consequence of cytomegalovirus infection.
Subject(s)
Bone Marrow Transplantation/adverse effects , Cytomegalovirus Infections/complications , Leukoencephalopathy, Progressive Multifocal/etiology , T-Lymphocytes/pathology , Adult , Brain/diagnostic imaging , Cell Division , Humans , Immunity, Cellular , Leukoencephalopathy, Progressive Multifocal/diagnosis , Magnetic Resonance Imaging , Male , Tomography, X-Ray ComputedABSTRACT
(1) Rats were fed on diets enriched with sucrose, beef tallow or corn oil and treated for 11-16 days with 50 mg of benfluorex per kg of body weight. By these times the growth rate and food intake were not significantly different from those of control rats. (2) Benfluorex approximately halved the concentration of circulating triacylglycerol in rats fed the beef tallow or sucrose diets. (3) It did not significantly alter the total lipoprotein lipase activity in diaphragm, heart and adipose tissue. (4) The clearance of triacylglycerols from chylomicrons exhibited two t 1/2 values of about 0.6 and 6.9 min in rats fed the beef tallow diet. Benfluorex did not significantly alter these values. (5) Benfluorex did not significantly alter the rate of appearance of triacylglycerol in the blood of rats injected with Triton WR 1339 to block triacylglycerol uptake. It did, however, decrease the rise in circulating glucose which presumably resulted from the stress of the procedure. (6) Benfluorex decreased the extent and duration of the rise in serum corticosterone when rats maintained on the corn oil diet were fed acutely with fructose. It also decreased the circulating concentrations of glycerol, triacylglycerol and glucose after fructose feeding. (7) Rats fed on the corn oil diet and then treated with benfluorex had lower concentrations of circulating glucose, triacylglycerol, glycerol and fatty acids after being injected with 2-deoxyglucose. (8) It is proposed that some of the long-term hypoglycaemic and hypotriglyceridaemic effects of benfluorex could be mediated indirectly through changes in endocrine balance, perhaps via the serotonergic system and in particular, by decreasing the effects of stress hormones relative to insulin. The implications of these findings are discussed in relation to controlling metabolism in stress conditions and for the management of obesity, diabetes and atherosclerosis.